Literature DB >> 12901891

Lyme borreliosis.

Ulrich R Hengge1, Andrea Tannapfel, Steven K Tyring, Raimund Erbel, Gabriele Arendt, Thomas Ruzicka.   

Abstract

Lyme borreliosis is a multi-organ infection caused by spirochetes of the Borrelia burgdorferi sensu lato group with its species B burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii, which are transmitted by ticks of the species Ixodes. Laboratory testing of Lyme borreliosis includes culture, antibody detection using ELISA with whole extracts or recombinant chimeric borrelia proteins, immunoblot, and PCR with different levels of sensitivity and specificity for each test. Common skin manifestations of Lyme borreliosis include erythema migrans, lymphocytoma, and acrodermatitis chronica atrophicans. The last two conditions are usually caused by B garinii and B afzelii, respectively, which are seen more frequently in Europe than in America. Late extracutaneous manifestations of Lyme borreliosis are characterised by carditis, neuroborreliosis, and arthritis. We present evidence-based treatment recommendations for Lyme borreliosis and review the prevention of Lyme borreliosis, including the Lyme vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901891     DOI: 10.1016/s1473-3099(03)00722-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  44 in total

1.  A twist on Lyme: the challenge of diagnosing European Lyme neuroborreliosis.

Authors:  Naila Makhani; Shaun K Morris; Andrea V Page; Jason Brophy; L Robbin Lindsay; Brenda L Banwell; Susan E Richardson
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

2.  Differential diagnosis of mesiotemporal lesions: case report of neurosyphilis.

Authors:  Rainer Scheid
Journal:  Neuroradiology       Date:  2006-03-28       Impact factor: 2.804

3.  Phagocytosis of Borrelia burgdorferi and Treponema pallidum potentiates innate immune activation and induces gamma interferon production.

Authors:  Meagan W Moore; Adriana R Cruz; Carson J LaVake; Amanda L Marzo; Christian H Eggers; Juan C Salazar; Justin D Radolf
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Poliomyelitis-like syndrome with matching magnetic resonance features in a case of Lyme neuroborreliosis.

Authors:  V Charles; T P Duprez; B Kabamba; A Ivanoiu; C J M Sindic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-10       Impact factor: 10.154

5.  Different Symptoms.

Authors:  Michael G Haufs
Journal:  Dtsch Arztebl Int       Date:  2009-08-03       Impact factor: 5.594

6.  A man with cardiac Lyme borreliosis.

Authors:  Jarne M van Hattem; Jan T Keijer; Robin Nijveldt
Journal:  CMAJ       Date:  2015-07-06       Impact factor: 8.262

7.  Genotyping and Quantifying Lyme Pathogen Strains by Deep Sequencing of the Outer Surface Protein C (ospC) Locus.

Authors:  Lia Di; Zhenmao Wan; Saymon Akther; Chunxiao Ying; Amanda Larracuente; Li Li; Chong Di; Roy Nunez; D Moses Cucura; Noel L Goddard; Konstantino Krampis; Wei-Gang Qiu
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

Review 8.  Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?

Authors:  M Pauschinger; M Noutsias; D Lassner; H-P Schultheiss; U Kuehl
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

9.  Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.

Authors:  Niklas Mattsson; Daniel Bremell; Rolf Anckarsäter; Kaj Blennow; Henrik Anckarsäter; Henrik Zetterberg; Lars Hagberg
Journal:  BMC Neurol       Date:  2010-06-22       Impact factor: 2.474

10.  Early production of IL-22 but not IL-17 by peripheral blood mononuclear cells exposed to live Borrelia burgdorferi: the role of monocytes and interleukin-1.

Authors:  Malte Bachmann; Katharina Horn; Ina Rudloff; Itamar Goren; Martin Holdener; Urs Christen; Nicole Darsow; Klaus-Peter Hunfeld; Ulrike Koehl; Peter Kind; Josef Pfeilschifter; Peter Kraiczy; Heiko Mühl
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.